Nexien BioPharma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NXEN research report →
Price Chart
About the company
Nexien BioPharma, Inc. , a pharmaceutical firm headquartered in Glendale, Colorado, concentrates its efforts on the research, advancement, and market introduction of cannabinoid-derived medications. The company utilizes both pre-clinical and clinical development paths to address a variety of diseases, medical conditions, and disorders.
- CEO
- Richard S. Greenberg
- IPO
- 2017
- Employees
- 10
- HQ
- Glendale, CO, US
Get TickerSpark's AI analysis on NXEN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $7.08K
- P/E
- -0.03
- PEG
- -0.00
- P/S
- 0.00
- P/B
- -0.02
- EV/EBITDA
- -935.16
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 77.94%
- ROIC
- 318.40%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-156,000
- Net Income
- $-239,000+34.0%
- EPS
- $-0.00+37.9%
- OCF Growth
- +21.3%
- FCF Growth
- +21.3%
- 52W High
- $0.01
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -0.88
- RSI (14)
- 1
- Avg Volume
- 596
No earnings-call transcripts are available for NXEN yet.
- Free Float
- 44.2%
- Shares Outstanding
- 70.77M
- Float Shares
- 31.27M
of shares held by institutions
1 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Advisor Group, Inc. | 18 | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 23, 24 | Greenberg Richard S | other | 1,000,000 |
| May 23, 24 | Wasoff Evan L | other | 2,000,000 |
| Oct 31, 23 | Greenberg Richard S | other | 250,000 |
| Oct 31, 23 | Wasoff Evan L | other | 250,000 |
| Jul 25, 23 | Goldfarb Robert I | other | 250,000 |
| Apr 1, 23 | Goldfarb Robert I | other | 250,000 |
| Aug 19, 20 | Goldfarb Robert I | other | 1,000,000 |
| Jul 25, 23 | Greenberg Richard S | other | 250,000 |
| Jul 25, 23 | Wasoff Evan L | other | 250,000 |
| Apr 1, 23 | Wasoff Evan L | other | 250,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NXEN coverage
Recent articles, reports, and earnings notes.
No research on NXEN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NXEN report →